
Commentary|Videos|June 15, 2025
Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma
Author(s)Meletios A. Dimopoulos, MD
Fact checked by: Ashling Wahner , Chris Ryan
Meletios A. Dimopoulos, MD, discusses efficacy and safety findings with elranatamab plus daratumumab and lenalidomide in newly diagnosed multiple myeloma.
Advertisement
Meletios A. Dimopoulos, MD, a professor and chairman in the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine, discussed efficacy and safety findings from part 1 of the MagnetisMM-6 trial (NCT05623020), which is investigating elranatamab-bcmm (Elrexfio) plus daratumumab (Darzalex) and lenalidomide (Revlimid) in patients with newly diagnosed multiple myeloma.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5






































